Genetic variants associated with circulating MMP1 levels near matrix metalloproteinase genes on chromosome 11q21-22 in Taiwanese: interaction with obesity by Hsuan-Li Huang et al.
Huang et al. BMC Medical Genetics 2013, 14:30
http://www.biomedcentral.com/1471-2350/14/30RESEARCH ARTICLE Open AccessGenetic variants associated with circulating
MMP1 levels near matrix metalloproteinase genes
on chromosome 11q21-22 in Taiwanese:
interaction with obesity
Hsuan-Li Huang1†, Semon Wu2†, Lung-An Hsu3,4, Ming-Sheng Teng5, Jeng-Feng Lin1, Yu-Chen Sun6 and
Yu-Lin Ko1,7*Abstract
Background: MMP1 is implicated in the pathogenesis of atherothrombotic cardiovascular disease. We aimed to
elucidate genetic determinants of inflammatory marker levels, including circulating MMP1, in Taiwanese, and their
association with obesity.
Methods: Five genetic polymorphisms around matrix metalloproteinase genes on chromosome 11q21-22 region
were genotyped in 519 subjects.
Results: After adjusting for clinical covariates, two polymorphisms were significantly associated with MMP1 levels,
rs1799750 and rs495366, using an additive inheritance model (P = 1.5x10-4 and P = 2.57x10-5, respectively). Using
dominant model, minor alleles of rs1799750 and rs495366 were associated with higher MMP1 levels (P = 1.3x10-4
and P = 1.95x10-5, respectively). In haplotype analysis, two haplotypes inferred from five SNPs (A2GATA and A1GATG)
were associated with MMP1 levels (P = 5x10-4 and P = 8.47x10-5, respectively). Subgroup and interaction analysis
revealed an association of rs1799750 and rs495366 with MMP1 levels only in non-obese subjects (P = 6.66x10-6 and
P = 4.38x10-5, respectively, and interaction P = 0.008 for rs1799750). Haplotype interaction analysis also showed
significant interaction for haplotype A1GATG (interaction P = 0.003).
Conclusions: Genotypes/haplotypes around MMP1 locus are associated with MMP1 levels in Taiwanese. Further,
since genotypes/haplotypes near MMP1 locus interact with obesity to set MMP1 levels, genetic determinants for
MMP1 level may be different between obese and non-obese individuals.
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Matrix metalloproteinases (MMPs) are a family of
Zn2+-dependent endopeptidases capable of cleaving
components of extracellular matrix, such as collagen,
proteoglycans and elastin [1,2].
For cardiovascular diseases, MMPs have been identi-
fied in human atherosclerotic plaque shoulders and* Correspondence: yulinkotw@yahoo.com.tw
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reproduction in any medium, provided the orregions of foam cell accumulation and may contribute to
plaque vulnerability [3,4]. Further, MMPs are suspected
to play an important role in the pathogenesis of athero-
sclerosis, restenosis, and myocardial repair following
myocardial infarction [3-5].
Matrix metalloproteinase 1 (MMP1), also called inter-
stitial collagenase, is a proteolytic enzyme able to de-
grade types I, II, and III collagen, which are resistant to
most proteinases [6,7]. Pathological studies have shown
that MMP1 is expressed by macrophages in atheroscler-
otic plaques and MMP1 expression is significantly in-
creased in vulnerable atherosclerotic plaques compared
with stable plaques, particularly in shoulder regions andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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MMP1 is also implicated in the regulation of the platelet
aggregation that follows plaque disruption which may
result in acute coronary syndrome [12]. These findings
suggested that MMP1 may play an important role in the
pathogenesis of atherothrombotic cardiovascular disease.
Recent studies have shown an association of MMP1
levels with a wide variety of disorders, including polycys-
tic kidney disease, rheumatoid arthritis, idiopathic pul-
monary fibrosis, congestive heart failure, and acute
myocardial infarction [13-17]. Promoter polymorphisms
of the MMP1 gene have also been associated with in-
creased MMP1 gene expression [18-20]. However, con-
troversial results were noted between MMP1 promoter
polymorphisms, circulating MMP1 levels and the risk of
cardiovascular disease [16,21-28]. Using a genome-wide
association scan, Cheng et al. identified variants near
MMP genes on chromosome 11q21-22 that were signifi-
cantly associated with serum MMP1 levels [29].
We analyzed five closely linked SNPs located near
MMP genes on chromosome 11q21-22 in an attempt to
elucidate the genetic determinants of circulating MMP1




A total of 519 Han Chinese subjects (264 men with a
mean age of 43.9 ± 9.4 years and 255 women with
a mean age of 45.8 ± 9.4 years) responded to aTable 1 Baseline characteristics of study subjects
Total
Number 519
Age (years) 44.8 ± 9.4
Body mass index (kg/m2) 24.1 ± 3.4
Current smokers (%) 19.8
CRP (mg/L) 1.0 ± 1.4
Fibrinogen (mg/dL) 260.3 ± 66.6
sE-selectin (μg/L) 52.6 ± 25.7
sP- selectin (ng/mL) 135.9 ± 114.1
SAA, (mg/L) 5.1 ± 10.1
sICAM1 (μg/L) 239.8 ± 113.2
sVCAM1 (μg/L) 488.0 ± 133.7
MMP1 (pg/mL) 486.9 ± 1213.4
MMP2 (ng/mL) 126.4 ± 40.8
MMP9 (ng/mL) 142.1 ± 111.8
MCP1 (pg/mL) 74.0 ± 61.0
sTNFRII (pg/mL) 3237.3 ± 922.3
IL6 (pg/mL) 4.0 ± 7.5
P value indicates male vs. female.questionnaire on their medical history and lifestyle char-
acteristics and were recruited during routine health ex-
aminations between Oct. 2003 and Sept. 2005 at the
Chang Gung Memorial Hospital. The subjects under-
went a physical examination that involved measurement
of height, weight, waist and hip circumference, and
blood pressure in the sitting position after 15 min of
rest. Fasting blood samples were obtained from each
subject. Exclusion criteria included a history of myocar-
dial infarction, stroke or transient ischemic attack, can-
cer, and current renal or liver disease. The clinical
characteristics and biometrics of the study population
are summarized in Table 1.
Obesity was defined as a body mass index (BMI) of 25
kg/m2, or more, according to the Asian criteria [30].
Current smokers were defined as those who smoked cig-
arettes regularly at the time of survey. All subjects pro-
vided written informed consent. The study was
approved by the Ethics Committee of the Tzu-Chi Me-
morial Hospital.
Genomic DNA extraction and genotyping
Genomic DNA was extracted, as previously reported
[31,32]. Oligonucleotide primers were generated to amp-
lify fragments of genomic DNA containing SNPs, as
reported on the NCBI SNP database (http://www.ncbi.
nlm.nih.gov/SNP). Five SNPs were analyzed due to
previous reports showing an association with MMP1
gene expression/level. Genotyping for SNPs rs11226373,
rs1799750 and rs495366 were performed by polymeraseMen Women P value
264 255
43.9 ± 9.4 45.8 ± 9.4 0.023
24.8 ± 3.1 23.4 ± 3.6 <0.001
35.2 3.9 <0.001
1.1 ± 1.4 1.0 ± 1.3 0.071
257.7 ± 68.6 263.2 ± 64.6 0.348
59.8 ± 27.0 45.0 ± 22.0 <0.001
149.2 ± 129.6 122.2 ± 94.0 0.004
5.4 ± 11.6 4.7 ± 8.4 0.485
243,8 ± 109.6 235.8 ± 116.8 0.281
490.4 ± 154.2 485.4 ± 108.8 0.647
355.1 ± 591.4 622.7 ± 1612.2 0.992
123.0 ± 41.9 129.9 ± 39.5 0.013
154.1 ± 112.8 129.7 ± 109.7 <0.001
80.9 ± 71.2 66.9 ± 47.4 0.006
3300.2 ± 966.8 3172.7 ± 871.3 0.116
4.2 ± 8.8 3.8 ± 5.8 0.426
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typing for SNP rs514921 (C_632711_10) and rs1144393
(C_7492493_10) were performed using TaqMan SNP
Genotyping Assays obtained from Applied Biosystem
(ABI, Foster City, CA, USA). Genotyping data are shown
in Additional file 1: Table S1.
Laboratory examination and assays
Medical history and blood sampling were obtained, as
previously reported [33]. Most markers, including serum
C-reactive protein (CRP), serum amyloid A (SAA), sol-
uble intercellular adhesive molecule (sICAM1), soluble
vascular cell adhesive molecule (sVCAM1), soluble E-
selectin (SELE), matrix metalloproteinase 2 (MMP2),
and matrix metalloproteinase 9 (MMP9) were measured
using a sandwich enzyme-linked immunosorbent assay
(ELISA) developed in-house. All in-house kits showed
good correlation when compared with commercially
available ELISA kits [34-36]. Circulating plasma matrix
metalloproteinase 1 (MMP1), Monocyte chemotactic
protein 1 (MCP1), soluble P-selectin (SELP), soluble
tumor necrosis factor receptor II (sTNFRII), and inter-
leukin 6 (IL6) were measured using commercially avail-
able ELISA kits from R&D (Minneapolis, MN, USA).
Mean intra-assay CVs from serum specimens were 7.1,
8.5, 2.1, 4.2, 4.1, 6.1 and 7.1%, and inter-assay CVs were
9.5, 8.1, 3.8, 6.8, 3.4, 8.8 and 9.1% for CRP, SAA, ICAM-
1, sVCAM1, SELE, MMP2,and MMP9 levels, respect-
ively. While the intra-assay CVs from plasma specimens
were 3.8, 3.0, 2.2, 3.1 and 5.5%, and inter-assay CVs were
5.7, 8.8, 4.1, 4.5 and 8.2% for MCP-1, SELP, sTNFRII,
IL6 and MMP1 levels, respectively.
Statistical analysis
The chi-square test was used to test for comparing cat-
egorical variable of smoking. The clinical characteristics
of the continuous variables were expressed as means ±
SD and tested by two-sample t-test or ANOVA. A gener-
alized linear model was used to analyze MMP1 level in
relation to predictors of the investigated genotypes and
confounders. CRP, SAA, IL6, ICAM1, VCAM1, SELE,
SELP, MMP1, MMP2, MMP9, MCP1, and sTNFRII were
logarithmically transformed prior to statistical analysis
to adhere to a normality assumption. The Bonferroni
method was used to correct for multiple comparisons
where applicable. A value of P < 0.05, using two-sided
tests, was considered statistically significant, whereas a
value of corrected P < 0.01 for genotype and P < 0.005
for haplotype analysis, respectively, was considered sig-
nificant after Bonferroni correction.
Interactions between each SNP, the level of MMP1,
and obesity status were tested with two-way ANOVA.
When interaction terms were significant, stratified ana-
lyses of the genetic variants of the genotypes (e.g., targetgenotypes affected by obesity) and MMP1 level were
performed to further investigate interactive effects while
controlling for other variables including age, gender, and
smoking. Measures of haplotype frequencies were esti-
mated using the expectation-maximization algorithm
implemented in HelixTree Genetics Analysis software
(Golden Helix, Bozeman, MT). In the haplotype analysis,
Coefficients and P values were estimated based on
haplotype trend regression analysis implemented in the
HelixTree program. The selected haplotype was com-
pared to all other unselected haplotypes. The analysis of
deviation from Hardy-Weinberg equilibrium, estimation
of linkage disequilibrium between polymorphisms, asso-
ciation of haplotypes with MMP1 level, and haplotype-
obesity interaction were performed using the Golden
Helix SVS Win32 7.3.1 software.Results
Clinical and biochemical characteristics
A summary of demographic features, clinical profiles,
and inflammatory biomarkers for the study participants
(stratified by sex) is provided in Table 1. No significant
deviation from the Hardy-Weinberg equilibrium was
detected for the studied polymorphisms (P = 0.90, 0.76,
0.56, 1.00 and 0.95 for SNPs rs11226373, rs1799750,
rs1144393, rs514921, and rs495366, respectively). Only
SNPs rs1144393 and rs514921 were in strong pairwise
linkage disequilibrium (Additional file 1: Figure S1).Associations of the MMP1 gene polymorphisms with
circulation levels of MMP1
To determine whether the MMP1 genotypes affected cir-
culating inflammatory marker levels, 13 inflammatory
markers were analyzed, including CRP, fibrinogen, SAA,
IL6, sICAM1, sVCAM1, sP- selectin, sP- selectin,
sTNFRII, MMP1, MMP2 MMP9, and MCP1. Our re-
sults showed that genetic variants in or around the
MMP1 gene were significantly associated with MMP1
levels in Taiwanese. After adjusting for clinical covari-
ates, significant associations with MMP1 level were ob-
served for two polymorphisms, rs1799750 and rs495366,
using an additive inheritance model (P = 1.5x10-4 and
P = 2.57x10-5, respectively). Furthermore, with dominant
model, minor alleles of rs1799750 and rs495366 were
found to be associated with a higher MMP1 level
(P = 1.3x10-4 and P = 1.95x10-5, respectively). These asso-
ciations remained statistically significant after multiple
comparisons adjustment with Bonferroni method in
additive and dominant model (Table 2). In contrast,
there was no significant difference between the studied
MMP1 genotypes and levels of other inflammatory bio-
markers (Additional file 1: Table S2).
Table 2 Association between MMP1 genotype and MMP1
levels
MMP1 genotype MMP1 levels P value Adjusted P value
rs11226373 AA 536.6 ± 1333.4 (376) 0.111 0.555
AG 321.7 ± 632.8 (120)
GG 838.0 ± 1898.8 (12)
AA 536.6 ± 1333.4 (376) 0.036 0.180
AG + GG 368.6 ± 829.9 (132)
rs1799750 2G/2G 323.2 ± 794.7 (206) 1.5x10-4 7.5 x10-4
2G/1G 543.9 ± 1294.1 (242)
1G/1G 895.5 ± 1921.5 (58)
2G/2G 323.2 ± 794.7 (206) 1.3x10-4 6.5 x10-4
2G/1G + 1G/1G 611.9 ± 1439.8 (300)
rs1144393 TT 482.6 ± 1222.6 (428) 0.334 1
TC 552.0 ± 1238.8 (80)
CC 380.8 (1)
TT 482.6 ± 1222.6 (428) 0.360 1
TC + CC 549.9 ± 1231.1 (81)
rs514921 AA 454.9 ± 1122.9 (405) 0.905 1
AG 667.9 ± 1601.6 (97)
GG 336.4 ± 260.2 (6)
AA 454.9 ± 1122.9 (405) 0.923 1
AG + GG 648.5 ± 1556.8 (103)
rs495366 AA 299.7 ± 729.6 (174) 2.57x10-5 1.29 x10-4
AG 561.7 ± 1352.7 (242)
GG 683.6 ± 1547.7 (91)
AA 299.7 ± 729.6 (174) 1.95x10-5 9.75 x10-5
AG + GG 594.9 ± 1407.3 (333)
P value, adjusted for age, sex, BMI, and smoking status.
Adjusted P values were computed by the Bonferroni method.
Table 3 Association of MMP1 locus haplotypes with MMP1 lev
SNP 1 SNP 2 SNP 3 SNP 4 SNP 5 Frequency
H1 A 2G T A A 38.56%
H2 A 1G T A G 17.47%
H3 A 2G T A G 9.66%
H4 A 2G T G A 6.61%
H5 G 2G T A A 5.62%
H6 A 1G C A G 5.48%
H7 A 1G T A A 4.47%
H8 G 1G T A G 2.87%
H9 A 1G T G G 2.65%
H10 G 2G T A G 1.81%
SNP1: rs11226373, SNP2: rs1799750, SNP3: rs1144393, SNP4: rs514921, SNP5: rs4953
Coefficients and P values were estimated based on haplotype trend regression anal
to all other unselected haplotypes; adjusted for age, sex, smoking, and BMI.
Adjusted P values were computed by the Bonferroni method.
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Because single SNP regression demonstrated that mul-
tiple sites within the MMP1 gene significantly affected
MMP1 level, haplotypes were inferred to capture pos-
sible allelic associations. In the present investigation, 10
common haplotypes (≥ 1% frequency) were derived from
five SNPs, accounting for 95.2% of all inferred haplo-
types. In haplotype analysis, two haplotypes inferred
from five SNPs (A2GTAA and A1GTAG) were found to
be associated with MMP1 level (P = 5.02x10-4 and
P = 8.47x10-5, respectively). The observed association be-
tween haplotypes (A2GTAA and A1GTAG) and MMP1
levels turn into borderline significant after multiple com-
parisons adjustment with Bonferroni method (Table 3).Interaction analysis
As presented in Table 4, after adjustment of clinical co-
variates, subgroup and interaction analysis revealed an
association of rs1799750 and rs495366 with MMP1
levels only in non-obese subjects (P = 6.66x10-6 and
P = 4.38x10-5, respectively, and interaction P = 0.008 for
rs1799750). In Additional file 1: Table S3, a significant
effect of obesity on the association between MMP1 hap-
lotypes and MMP1 level was also noted in haplotype
interaction analysis after adjusting for age, gender, and
smoking, with the association found predominantly
in non-obese subjects (P = 2.29x10-6 for haplotype
A1GTAG and P = 0.002 for haplotype A2GTAA, and
interaction P = 0.003 for A1GTAG). After stringent
Bonferroni correction for multiple interaction tests, bor-
derline significance was also noted with H5 (G2GTAA)
for non-obese subjects and H8 (G1GTAG) for obese
subjects.el
Coefficient SE t.stat P value Adjusted P value
−0.2311 0.0660 −3.5029 5.02x10-4 0.005
0.3304 0.0834 3.9635 8.47x10-5 8.47 x10-4
0.1597 0.1103 1.4481 0.148 1
−0.0533 0.1570 −0.3392 0.735 1
−0.2479 0.1394 −1.7782 0.076 0.760
0.1326 0.1440 0.9212 0.357 1
0.1285 0.1697 0.7572 0.449 1
−0.4000 0.2532 −1.5798 0.115 1
0.2969 0.2400 1.2373 0.217 1
−0.1032 0.2987 −0.3457 0.730 1
66.
ysis implemented in the HelixTree program. The selected haplotype compared
Table 4 Interaction effect of obesity on the association between MMP1 genotypes and MMP1 levels
Non-obese Obese
SNP N Coefficient SE t value P value N Coefficient SE t value P value Interaction P
rs11226373 322 −0.1193 0.0543 −2.1944 0.029 186 0.0305 0.0696 0.4374 0.662 0.100
rs1799750 320 0.1844 0.0402 4.5816 6.66x10-6 186 0.0041 0.0539 0.0752 0.940 0.008
rs1144393 323 0.0324 0.0741 0.4368 0.663 186 0.1128 0.0937 1.2039 0.230 0.536
rs514921 323 0.0097 0.0600 0.1623 0.871 185 0.0147 0.0897 0.1642 0.870 0.983
rs495366 321 0.1630 0.0393 4.1443 4.38x10-5 186 0.0689 0.0472 1.4608 0.146 0.119
Additive genetic model; Coefficients and P values were performed using the linear regression model under the assumption of an additive effect of the minor
allele; adjusted for age, sex, and smoking.
Huang et al. BMC Medical Genetics 2013, 14:30 Page 5 of 7
http://www.biomedcentral.com/1471-2350/14/30Discussion
This investigation analyzed the association of genetic
variants in or around the MMP1 gene with inflammatory
marker levels in Taiwanese. The genotypes/haplotypes of
the SNPs studied were associated with MMP1 levels, but
not with levels of 12 other inflammatory markers. Fur-
thermore, we found that genotypes/haplotypes around
the MMP1 locus interacted with obesity to set the
MMP1 level, with the association occurring predomin-
antly in non-obese subjects. These results provided the
first evidence that genetic determinants for MMP1 level
may vary between obese vs. non-obese individuals.
The role of SNPs found in or around the MMP1 gene
in MMP1 gene expression/MMP1 levels has recently
been examined. Rutter et al. [18] first reported that a
1G/2G polymorphism at -1607 bp (rs1799750) in the
MMP-1 promoter region with the 2G allele creates an
Ets binding site and augments transcription. Affara et al.
[20] also revealed an increase in MMP1 gene expression
of the 2G allele. Pearce et al. [19] reported two other
promoter polymorphisms on the MMP1 gene, the
-519A > G (rs1144393) and -340T > C (rs514921) poly-
morphisms. In vitro assays showed that, compared with
the A519-T−340 haplotype, the A−519-C−340 and G−519-
T−340 haplotype had lower promoter activity, whereas
the G−519-C−340 haplotype had greater promoter strength
in driving gene expression in human macrophages.
However, the association between -519A > G and -340T
> C polymorphisms and MMP1 level has not been
reported and the association between -1607 1G/2G poly-
morphism and MMP1 level has been controversial. Abd-
Allah et al. [28] showed higher MMP1 levels with the
2G allele of the -1607 1G/2G polymorphism in a dis-
eased population; Chen et al. [17] revealed lower MMP1
level with -1607 2G allele in rheumatoid arthritic pa-
tients, while two other reports showed no evidence of
the association [16,27] .
By using a genome-wide association scan, the stron-
gest evidence of an association between MMP1 SNPs
and MMP1 level was provided by Cheng et al. [29]. In
that study, variants near MMP genes on chromosome
11q21-22 were associated with serum MMP1 levels, withthe peak association noted at rs495366 with lower
MMP1 levels in subjects containing the minor T allele
(equal to A allele in our genotypic data). We found re-
sults similar to those reported by Cheng et al. [29], i.e.,
we showed a significantly lower MMP1 level in the A
allele of the rs495366. In addition, we also found incom-
plete linkage disequilibrium of the studied polymor-
phisms with the A allele of the rs495366 linked to 2G
allele of the -1607 1G/2G polymorphism, which was as-
sociated with higher MMP1 gene expression in previous
reports but lower MMP1 level in our study. These re-
sults suggested that the -1607 1G/2G polymorphism, al-
though affecting MMP1 gene expression, may not be the
major determinant of MMP1 level in Taiwanese. Because
the rs495366 polymorphism was located far away from
the MMP1 gene, it is likely that unidentified polymorph-
ism(s) may be present between the studied SNPs that
may affect the gene expression and result in different
MMP1 levels.
Interaction with obesity
The interplay between genetic and environmental factors
is important in phenotype development of complex
traits. We found an association of MMP1 genotypes/
haplotypes with MMP1 level predominantly in non-
obese subjects. Our previous studies showed that the as-
sociation between genetic variants and inflammatory
marker levels occurred predominantly in non-obese
subjects [37,38] or obese subjects [39,40]. It has been
suggested that macrophage accumulation in adipose
tissue has a central role in stimulating MMP1 and
MMP3 production by preadipocytes, mediated by IL1β
and TNFα, supporting the role of macrophages in
stimulating tissue remodeling during adipose tissue ex-
pansion in obesity [41,42]. We found an association of
MMP1 genotypes/haplotypes with MMP1 level pre-
dominantly in non-obese subjects. It could be due to
the small sample size in the obese group. Otherwise,
the present results suggest the possibility that obese
subjects who have high levels of many metabolic and
inflammatory risk factors may mask the genetically as-
sociated changes.
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levels
Several groups have shown an association between the
1G/2G polymorphism in the MMP1 gene and coronary
artery disease [22,24], myocardial infarction [19,21], and
peripheral artery disease [23]. In a meta-analysis of 39
studies with 42269 individuals, Li et al. [43] provide evi-
dence that MMP1 -1607 polymorphism has a mild to
moderate effect on the incidence of coronary disease. In
two meta-analyses with 12 and 33 studies, respectively,
Liu et al. [44,45] also found an association between the
1G/2G polymorphism at -1607 bp in the MMP-1 pro-
moter region and the risk of colorectal cancer and risk
of metastasis in some cancers. Pearce et al. [19] reported
two other promoter polymorphisms on the MMP1 gene,
the -519A > G and -340T > C polymorphisms, with
haplotype effects on the risk of myocardial infarction.
Han et al. [26] investigated the -519A > G and –340T >
C promoter polymorphisms and found an association
between the MMP1 promoter genotypes/haplotypes and
the risk of acute coronary syndrome in Chinese. How-
ever, Hlatky et al. [25] found no evidence of an associ-
ation between circulating MMP1 levels and the risk of
AMI. Thus, further studies may be necessary to eluci-
date the role of MMP1 SNPs/levels in the development
of cardiovascular disease.Limitation of the study
The main limitation of our study was its modest sample
size, which was not analyzed in any functional manner
and showed only an arguable relationship with disease.
However, significant differences were noted even when
Bonferroni correction was stringently applied for mul-
tiple tests. The replication of our results using a second
cohort, especially with a larger sample size and a differ-
ent ethnic population, would strengthen our analysis. In
addition, the cross-sectional nature of the present study
limits our ability to infer a causal relation between
MMP1 variants, MMP1 level, and various inflammation-
related disorders.Conclusions
In conclusion, we found that the association between
MMP1 gene polymorphisms and MMP1 level was
dependent on obesity status. The polymorphism(s) that
affected both MMP1 gene expression and MMP1 level
require further study. Because our evidence suggested an
association between MMP1 gene polymorphisms and
MMP1 levels, the discovery of causative unidentified
polymorphisms will be important in elucidating the
mechanism of MMP1 on cancer and atherosclerotic car-
diovascular disease.Additional file
Additional file 1: The association between MMP1 haplotypes and
MMP1 levels.
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